(Health-NewsWire.Net, November 04, 2017 ) Original Content: Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia/ventilator-associated pneumonia (HAP/VAP), and surgical site infection (SSI).
The pharmaceutical industry's battle against Gram-negative bacteria requires ongoing development and novel, innovative approaches for the development of new antibiotics as well as non-antibiotic based approaches. Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D during this century, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current future generations, including in developed countries. Consequently, industry and governments have recently ramped up their involvement in this space, and several promising antibiotics are now in the late-stage development.
For more information about this report: http://www.reportsweb.com/pharmapoint-healthcare-associated-gram-negative-infections-global-drug-forecast-and-market-analysis-to-2026
Scope
-Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. -Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. -Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM. -Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. -Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011205985/sample Scope
-Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. -Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. -Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM. -Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. -Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies Mentioned:
Pfizer Merck& Co. The Medicines Company Shionogi & Co., Ltd. Tetraphase Pharmaceuticals Inc. MerLion Pharmaceuticals Pte., Ltd. Achaogen Aridis Pharmaceuticals
Inquire for Report at http://www.reportsweb.com/inquiry&RW00011205985/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|